Antibody Discovery
In the competitive landscape of antibody therapeutics, the primary bottleneck has shifted from mere "binding" to "developability." To drive high-value lead generation, your service narrative must pivot from standard screening to AI-integrated molecular generation that mitigates downstream CMC risks.
AlfaBodY's Advantages
● Enabled for Difficult Targets
● Closed-loop Dry wet Iteration with 3 week cycle
● High Efficiency: <300 sequences → better molecule
● Fast: PCC+ in 8 months
● Low CMC Risk: Developability co optimized
● Comprehensive Data Package: In vivo/vitro + stable cell line
● Clinically De-risked: Epitope aligned with validated template antibody
● Accelerated Clinical Pathway: Potential bypass phase 2
Service Process
Case Study
Case 1: Generation of mAb Blocking Both TargetA/B
TargetA and TargetB exhibit only 55.65% homology, presenting a substantial barrier for the generation of high-affinity cross-reactive antibodies. Standard discovery workflows often lead to unbalanced potency or loss of binding for the less conserved target.
AlfaBodY Solution:
● Precision Screening: Screened 222 candidate antibodies across four intensive rounds of selection.
● Synchronized Optimization: Boosting anti-TargetA affinity while simultaneously maintaining anti-TargetB affinity each round.
● In Vitro Potency: Cellular functional assays demonstrated exceeding the primary reference benchmark.
● In Vivo Proof-of-Concept: Animal models confirmed statistically significant superior efficacy compared to the benchmark, validating the therapeutic potential of the dual-blockade mechanism.
Case 2: Overcoming GPCR Discovery Challenges—High-Affinity GIPR mAb Generation
